Exebacase联合标准抗菌药物治疗金黄色葡萄球菌血流感染及右侧感染性心内膜炎:一项3期优效性设计安慰剂对照随机临床试验(DISRUPT)
DISRUPT是一项3期优效性设计随机对照试验,评估单剂静脉Exebacase联合标准抗菌药物对比安慰剂联合标准抗菌药物治疗金黄色葡萄球菌血流感染/心内膜炎。研究因无效性提前终止,共随机259例;MRSA人群(n=97)第14天临床应答率Exebacase组50.0%(32/64)对单纯抗菌药物组60.6%(20/33),P=0.392,未达优效。
要点
- 在MRSA血流感染/心内膜炎患者中,Exebacase联合抗菌药物未改善第14天临床应答。
- MRSA人群第14天临床应答率Exebacase组50.0%(32/64)对单纯抗菌药物组60.6%(20/33),P=0.392。
- 研究因无效性提前终止,总体不良事件发生率组间相似,未报告Exebacase相关超敏不良事件。
核心结论
- Exebacase联合抗菌药物未能改善MRSA血流感染/心内膜炎患者第14天临床应答。
- 该结果与2期数据中Exebacase联合抗菌药物治疗MRSA血流感染/心内膜炎的概念验证结果不同,原文称此结果出乎意料。
- 单纯抗菌药物组的临床应答率高于2期研究中观察到的水平。
- 研究人群异质性以及2期或3期研究样本量相对较小,可能增加了第14天临床结局多个组成部分出现不平衡的概率。
- 该研究为未来金黄色葡萄球菌血流感染/心内膜炎的优效性研究提供了经验教训。
研究设计与样本
- DISRUPT为优效性设计3期研究,金黄色葡萄球菌菌血症/心内膜炎患者随机接受单剂静脉Exebacase或安慰剂,并联合标准抗菌药物治疗。
- 主要疗效结局为MRSA人群第14天临床应答。
- 研究基于非盲数据安全监查委员会的建议因无效性停止,停止前共随机259例患者。
- 临床试验注册号NCT04160468。
主要发现
- MRSA人群(n=97)第14天临床应答率:Exebacase联合抗菌药物组50.0%(32/64)对单纯抗菌药物组60.6%(20/33),P=0.392。
- 总体不良事件发生率组间相似。
- 未报告与Exebacase相关的超敏不良事件。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 研究基于非盲数据安全监查委员会的建议因无效性停止。
- 研究人群存在异质性。
- 2期或3期研究样本量相对较小,可能增加了第14天临床结局多个组成部分出现不平衡的概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel treatments are needed for Staphylococcus aureus bacteremia, particularly for methicillin-resistant S. aureus (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that is rapidly bactericidal and synergizes with antibiotics. METHODS: In Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT), a superiority-design phase 3 study, patients with S. aureus bacteremia/endocarditis were randomly assigned to receive a single dose of intravenous exebacase or placebo in addition to standard-of-care antibiotics. The primary efficacy outcome was clinical response at day 14 in the MRSA population. RESULTS: A total of 259 patients were randomized before the study was stopped for futility based on the recommendation of the unblinded Data Safety Monitoring Board. Clinical response rates at day 14 in the MRSA population (n = 97) were 50.0% (exebacase + antibiotics; 32/64) versus 60.6% (antibiotics alone; 20/33) (P = .392). Overall, rates of adverse events were similar across groups. No adverse events of hypersensitivity related to exebacase were reported. CONCLUSIONS: Exebacase + antibiotics failed to improve clinical response at day 14 in patients with MRSA bacteremia/endocarditis. This result was unexpected based on phase 2 data that established proof-of-concept for exebacase + antibiotics in patients with MRSA bacteremia/endocarditis. In the antibiotics-alone group, the clinical response rate was higher than that seen in phase 2. Heterogeneity within the study population and a relatively small sample size in either the phase 2 or phase 3 studies may have increased the probability of imbalances in the multiple components of day 14 clinical outcome. This study provides lessons for future superiority studies in S. aureus bacteremia/endocarditis. Clinical Trials Registration.NCT04160468.
引用
- Fowler VG, Das AF, Lipka-Diamond J, et al. Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT). Clin Infect Dis. 2024. PMID: 38297916. doi:10.1093/cid/ciae043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。